Skip to content

KPV Side Effects: Safety Profile, Risks & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Side Effects

KPV has demonstrated a favorable safety profile in preclinical studies. No acute toxicity has been reported in animal models at therapeutic doses, and the peptide does not appear to broadly suppress immune function in the way that corticosteroids or other immunosuppressive drugs do.

Commonly Reported (Anecdotal):

  • Mild injection site reactions (redness, tenderness)
  • Mild gastrointestinal discomfort (nausea, loose stools)
  • Temporary skin redness or dryness with topical application

Less Commonly Reported:

  • Allergic reactions to compound ingredients (redness, hives, stinging)
  • Fatigue
  • Headache

Safety Advantages: Unlike many anti-inflammatory medications, KPV does not appear to increase infection risk, cause tissue thinning, or produce the metabolic side effects associated with long-term corticosteroid use. Its targeted mechanism of NF-kB inhibition may provide anti-inflammatory benefits with a narrower side effect profile than broad-spectrum immunosuppressants.

Important Limitations: Long-term human safety data do not exist. KPV products from unregulated sources carry contamination risks, and batch-to-batch variability in purity and potency is a concern. Any use should be discussed with a qualified healthcare provider.

Frequently Asked Questions

KPV has demonstrated a favorable safety profile in preclinical studies. Reported side effects are generally mild and may include injection site irritation, mild nausea, and occasional gastrointestinal discomfort. Unlike corticosteroids, KPV does not appear to suppress immune function broadly. Long-term human safety data are not available.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
  2. Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602.
  3. Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628-1640.
  4. Dalmasso G, Nguyen HTT, Yan Y, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357.
  5. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331.
  6. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73.
  7. Luger TA, Scholzen TE, Brzoska T, Bohm M. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci. 2003;994:133-140.
  8. Luger TA, Brzoska T. Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66 Suppl 3:iii52-iii55.
  9. Catania A, Rajora N, Capsoni F, Minonzio F, Star RA, Lipton JM. The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides. 1996;17(4):675-679.
  10. Singh M, Mukhopadhyay K. Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide. Biomed Res Int. 2014;2014:874610.
  11. Yoon SW, Shin DH, Kim JS, et al. Lysine-proline-valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kB pathway. J Dermatol Sci. 2025.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”